pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
216
stories
20d
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
21d
Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes
raps
21d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
21d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
21d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
21d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
21d
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
endpoints
21d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
21d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
22d
5 new drug launches that defied industry expectations
biospace
22d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
23d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
27d
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
28d
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
29d
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
stat
Oct 19, 26
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
Oct 16, 26
CHMP endorses Eli Lilly’s GLP-1 pill and three other new drugs
endpoints
Oct 15, 26
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
Oct 15, 26
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
biospace
Oct 14, 26
STAT+: FDA adcomm members’ ties to industry under scrutiny
stat
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
Oct 14, 26
New study examines GLP-1 impact on interactions with criminal justice system, employment, housing stability
stat
Oct 13, 26
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 6, 26
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
biospace
Oct 2, 26
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
Oct 1, 26
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
← prev
page 2 of 8
next →